ECSP088270A - Derivados de (indol-3-il)-heterociclo como agonistas del receptor cannabinoide cb1 - Google Patents

Derivados de (indol-3-il)-heterociclo como agonistas del receptor cannabinoide cb1

Info

Publication number
ECSP088270A
ECSP088270A EC2008008270A ECSP088270A ECSP088270A EC SP088270 A ECSP088270 A EC SP088270A EC 2008008270 A EC2008008270 A EC 2008008270A EC SP088270 A ECSP088270 A EC SP088270A EC SP088270 A ECSP088270 A EC SP088270A
Authority
EC
Ecuador
Prior art keywords
derivatives
agnists
heterocicle
cannabinoid
indol
Prior art date
Application number
EC2008008270A
Other languages
English (en)
Inventor
Julia Adam-Worrall
Angus John Morrison
Takao Kiyoi
Paul David Ratcliffe
Stuart John Francis
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of ECSP088270A publication Critical patent/ECSP088270A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

La invención se refiere a derivados de indol que tienen la Fórmula general (I), en donde A, X1, X2, X3, Y, R1, R2, R3 y R4 tienen las definiciones indicadas en las reivindicaciones, o a una sal farmacéuticamente aceptable de los mismos, a composiciones farmacéuticas que los comprenden y al uso de dichos derivados de indol en el tratamiento del dolor.
EC2008008270A 2005-08-23 2008-03-13 Derivados de (indol-3-il)-heterociclo como agonistas del receptor cannabinoide cb1 ECSP088270A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05107725 2005-08-23

Publications (1)

Publication Number Publication Date
ECSP088270A true ECSP088270A (es) 2008-04-28

Family

ID=35539284

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008270A ECSP088270A (es) 2005-08-23 2008-03-13 Derivados de (indol-3-il)-heterociclo como agonistas del receptor cannabinoide cb1

Country Status (18)

Country Link
EP (1) EP1919471B1 (es)
JP (1) JP5283505B2 (es)
KR (1) KR20080038239A (es)
CN (1) CN101272783B (es)
AR (1) AR055384A1 (es)
AU (1) AU2006283884B2 (es)
BR (1) BRPI0615201A2 (es)
CA (1) CA2619038A1 (es)
EC (1) ECSP088270A (es)
IL (1) IL189390A0 (es)
MX (1) MX2008002539A (es)
NO (1) NO20080750L (es)
NZ (1) NZ566007A (es)
PE (1) PE20070236A1 (es)
RU (1) RU2008110961A (es)
TW (1) TW200745096A (es)
WO (1) WO2007023143A1 (es)
ZA (1) ZA200801519B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI330635B (en) 2004-03-05 2010-09-21 Organon Nv (indol-3-yl)-heterocycle derivatives
US7763732B2 (en) 2005-08-24 2010-07-27 N.V. Organon Indole derivatives
TW200848417A (en) * 2007-02-22 2008-12-16 Organon Nv Indole derivatives
ES2548764T3 (es) * 2007-03-30 2015-10-20 Janssen Pharmaceutica N.V. Agonistas de cannabinoides de bencimidazol
US8648190B2 (en) 2009-01-16 2014-02-11 Daiso Co., Ltd. Process for producing 2-hydroxymethylmorpholine salt
US9310374B2 (en) * 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
KR102114323B1 (ko) * 2013-12-09 2020-05-22 이니스트에스티 주식회사 광학활성 1-(인돌린-5-일)프로판-2-올 유도체의 제조방법
WO2017083306A1 (en) 2015-11-09 2017-05-18 R.P. Scherer Technologies, Llc Anti-cd22 antibody-maytansine conjugates and methods of use thereof
WO2017097732A1 (en) * 2015-12-09 2017-06-15 F. Hoffmann-La Roche Ag Phenyl derivatives as cannabinoid receptor 2 agonists
CN115667212A (zh) * 2020-05-29 2023-01-31 富士胶片富山化学株式会社 高纯度的n-(5-甲氧基-2-苯氧基苯基)甲磺酰胺及其制造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR118000A0 (en) * 2000-11-02 2000-11-23 Amrad Operations Pty. Limited Therapeutic molecules and methods
TW200402417A (en) * 2002-06-21 2004-02-16 Akzo Nobel Nv 1-[(Indol-3-yl)carbonyl]piperazine derivatives
BR0314872A (pt) * 2002-10-18 2005-08-02 Pfizer Prod Inc Ligandos do receptor canabinóide e usos dos mesmos
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
TWI330635B (en) * 2004-03-05 2010-09-21 Organon Nv (indol-3-yl)-heterocycle derivatives

Also Published As

Publication number Publication date
ZA200801519B (en) 2008-12-31
IL189390A0 (en) 2008-06-05
RU2008110961A (ru) 2009-09-27
JP5283505B2 (ja) 2013-09-04
EP1919471B1 (en) 2014-01-08
KR20080038239A (ko) 2008-05-02
AU2006283884A1 (en) 2007-03-01
CN101272783B (zh) 2011-05-25
AR055384A1 (es) 2007-08-22
AU2006283884B2 (en) 2011-06-02
CN101272783A (zh) 2008-09-24
WO2007023143A1 (en) 2007-03-01
BRPI0615201A2 (pt) 2011-05-10
NO20080750L (no) 2008-05-14
MX2008002539A (es) 2008-03-14
EP1919471A1 (en) 2008-05-14
JP2009506010A (ja) 2009-02-12
NZ566007A (en) 2009-12-24
PE20070236A1 (es) 2007-04-16
CA2619038A1 (en) 2007-03-01
TW200745096A (en) 2007-12-16

Similar Documents

Publication Publication Date Title
ECSP099663A (es) Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y métodos para utilizar la misma
CR11819A (es) Compuestos de isoindolina 5-sustituidos
ECSP088549A (es) Nuevos derivados de pirrol fusionado
UY30500A1 (es) Compuestos de azabencimidazolilo
CL2008002539A1 (es) Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral
GT200600518A (es) Derivados de pirimidina
CR10712A (es) Derivados de quinazolinona 5-sustituidos como agentes antitumorales
CL2008002538A1 (es) Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral
DE602007013440D1 (de) Substituierte indole
UY29058A1 (es) Compuestos de isoindolona y su uso como potenciadores del receptor metabotropico de glutamato
DE602008002934D1 (de) 2-cyclopropylthiazolderivate
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
NO20091395L (no) Nye tiofenderivater
UY28941A1 (es) Indazoles sustituidos, composiciones que los contienen, procedimiento de preparacion y su uso
CR9069A (es) Derivados de indol tetraciclicos como agentes antiviricos
EA201170703A1 (ru) Производные адамантилбензамида
SV2009003281A (es) Inhibidores espiro cetona de acetil-coa carboxilasa.0
ATE447568T1 (de) Neue pyrinderivate
DK1697371T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
UY31071A1 (es) Derivados heterociclicos sustituidos y su uso farmaceutico y composiciones
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
CY1114793T1 (el) Παραγωγα αμινοπυραζολιου
NI201100130A (es) Derivados de pirimidin indol para el tratamiento de cáncer.
ECSP088677A (es) Piperazinas y piperidinas como potenciadores 157 del mglur5
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren